Literature DB >> 8261827

5-hydroxytryptamine 3-receptor antagonist modulates gallbladder emptying and motilin release induced by erythromycin.

S Fiorucci1, L Santucci, A Morelli.   

Abstract

In the present study we evaluated the effect of ondansetron (formerly indicated as GR38032F), a potent and selective type-3 5-hydroxytryptamine receptor antagonist, on erythromycin-induced gallbladder emptying and motilin release, as well as gallbladder emptying induced by a regular meal in healthy volunteers. Gallbladder emptying was evaluated by sonography. Ondansetron, at the dose of 0.05 mg/kg, significantly reduced (P < 0.001 by ANOVA) the gallbladder emptying induced by 2 mg/kg/hr erythromycin, but did not increase basal gallbladder volume or inhibit gallbladder emptying induced by a regular meal. Ondansetron also inhibited the motilin release induced by erythromycin (P < 0.001, by ANOVA). These results suggest that serotoninergic mechanisms modulate the effects of erythromycin on the gastrointestinal tract. The exact site of action of ondansetron remains to be identified.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8261827     DOI: 10.1007/bf01299902

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

Review 1.  5-Hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders.

Authors:  B Costall; R J Naylor
Journal:  Scand J Gastroenterol       Date:  1990-08       Impact factor: 2.423

2.  Erythromycin is a motilin receptor agonist.

Authors:  T Peeters; G Matthijs; I Depoortere; T Cachet; J Hoogmartens; G Vantrappen
Journal:  Am J Physiol       Date:  1989-09

3.  The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig.

Authors:  B Costall; S J Gunning; R J Naylor; M B Tyers
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

4.  Changes in plasma motilin concentration and gastrointestinal contractile activity in conscious dogs.

Authors:  Z Itoh; S Takeuchi; I Aizawa; K Mori; T Taminato; Y Seino; H Imura; N Yanaihara
Journal:  Am J Dig Dis       Date:  1978-10

Review 5.  Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.

Authors:  M Marty
Journal:  Eur J Cancer Clin Oncol       Date:  1989

6.  Involvement of 5-hydroxytryptamine 3 receptors in regulation of interdigestive gastric contractions by motilin in the dog.

Authors:  Z Itoh; A Mizumoto; Y Iwanaga; N Yoshida; K Torii; K Wakabayashi
Journal:  Gastroenterology       Date:  1991-04       Impact factor: 22.682

7.  Structure-activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract.

Authors:  Z Itoh; T Suzuki; M Nakaya; M Inoue; H Arai; K Wakabayashi
Journal:  Am J Physiol       Date:  1985-03

8.  Erythromycin stimulates gallbladder emptying and motilin release by atropine-sensitive pathways.

Authors:  S Fiorucci; R Bosso; A Morelli
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

9.  Gallbladder contraction and its relationship to interdigestive duodenal motor activity in normal human subjects.

Authors:  L Marzio; M Neri; F Capone; F Di Felice; C De Angelis; A Mezzetti; F Cuccurullo
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

10.  Studies on the causal relationship between gall-bladder emptying and motilin release in man.

Authors:  T Svenberg; I Nilsson; K Samuelson; R D Welbourn
Journal:  Acta Chir Scand Suppl       Date:  1984
View more
  2 in total

Review 1.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

2.  Motilin induces gall bladder emptying and antral contractions in the fasted state in humans.

Authors:  Y C Luiking; T L Peeters; M F Stolk; V B Nieuwenhuijs; P Portincasa; I Depoortere; G P van Berge Henegouwen; L M Akkermans
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.